Inhibikase Therapeutics(IKT) - 2025 Q4 - Annual Results

Exhibit 99.1 Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity WILMINGTON, Del., March 26, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the year ended December 31, 2025 and highlighted recent developments. "The fourth quarter of 2 ...